San Francisco, January 13, 2020 – Recardio Inc., a clinical-stage life science company focusing on therapies for cardiovascular diseases, was participating in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
The company presented its technology and clinical therapy program for cardiovascular diseases with its ongoing global, randomized, double-blind, placebo-controlled, safety and efficacy Phase 2 Study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction.
The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
More information about the clinical program is available by visiting the “clinicaltrials.gov” website at the following link: https://clinicaltrials.gov/ct2/show/NCT03486080
Recardio Inc. is a clinical-stage life science company focusing on therapies for cardiovascular and other selected diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. In addition to its current Phase 2 clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. In addition other development programs are in preclinical stage.
For more information, visit: http://www.recardio.eu/